Lisinopril and Rosuvastatin Interaction: Safety, Monitoring, and What Prescribers Check

Why These Two Drugs Are Prescribed Together

Hypertension and hyperlipidemia overlap in roughly 30% of U.S. adults over age 45, according to NHANES data analyzed by the CDC. Treating both conditions simultaneously is not optional for these patients. It is standard practice.

Lisinopril, an ACE inhibitor approved by the FDA in 1987, remains one of the most prescribed antihypertensives in the United States, with over 88 million dispensed prescriptions in 2022 per IQVIA data. Rosuvastatin (brand name Crestor) ranks among the top three statins by prescription volume. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly recommends statin therapy for patients with hypertension who meet ASCVD risk thresholds of 7.5% or higher over 10 years [1]. Prescribers reach for this pairing because the drugs address two independent, additive contributors to atherosclerotic cardiovascular disease (ASCVD): elevated blood pressure and elevated LDL-C.

The HOPE-3 trial (N=12,705) demonstrated that combining lipid-lowering therapy (rosuvastatin 10 mg) with blood pressure reduction produced a 25% relative risk reduction in major cardiovascular events among intermediate-risk patients, compared to placebo for both [2]. That trial used candesartan/hydrochlorothiazide rather than lisinopril, but the pharmacologic rationale applies to any ACE inhibitor-statin pairing: the benefits are additive because the mechanisms are independent.

Pharmacokinetic Profile: Why No Interaction Exists

The absence of interaction between lisinopril and rosuvastatin comes down to non-overlapping metabolic pathways. Neither drug competes with the other for enzymes, transporters, or binding sites.

Lisinopril is pharmacokinetically unusual among ACE inhibitors. It is the only ACE inhibitor that is not a prodrug, meaning it requires no hepatic activation. According to the FDA-approved prescribing information, lisinopril does not bind to plasma proteins other than ACE itself, is not metabolized by any cytochrome P450 enzyme, and is excreted entirely unchanged in the urine [3]. This profile makes lisinopril one of the least interaction-prone antihypertensives available. It simply has no metabolic machinery to interfere with.

Rosuvastatin, for its part, undergoes only minimal metabolism through CYP2C9 (approximately 10% of elimination), with the vast majority of the dose excreted unchanged in feces via biliary secretion [4]. Rosuvastatin is a substrate of organic anion-transporting polypeptide 1B1 (OATP1B1), OATP1B3, and breast cancer resistance protein (BCRP). Drugs that inhibit these transporters (cyclosporine, certain protease inhibitors, gemfibrozil) can increase rosuvastatin exposure by 5- to 7-fold. Lisinopril does not interact with any of these transporters.

A 2018 systematic review of ACE inhibitor-statin combinations published in the British Journal of Clinical Pharmacology found no evidence of altered pharmacokinetics when ACE inhibitors were co-administered with statins across 14 studies [5]. The authors specifically noted that "the combination of an ACE inhibitor and a statin does not require dose adjustment of either agent based on pharmacokinetic grounds."

What the Major Drug Interaction Databases Say

Every major clinical decision-support database rates this combination as having no significant interaction. That consensus matters.

Lexicomp, the database embedded in most U.S. hospital electronic health records, does not flag a lisinopril-rosuvastatin interaction at any severity level [6]. Micromedex, used widely in pharmacy practice, returns no interaction record for this pair. Clinical Pharmacology (Elsevier) similarly reports no interaction.

The FDA prescribing information for rosuvastatin lists specific drugs that require dose caps or avoidance: cyclosporine (contraindicated above rosuvastatin 5 mg), gemfibrozil (avoid combination), and certain HIV protease inhibitors [4]. ACE inhibitors, including lisinopril, do not appear anywhere in the drug interaction section. The lisinopril label is equally silent about statins.

This does not mean monitoring is unnecessary. It means the monitoring required is the routine monitoring that each drug demands independently, not interaction-specific surveillance.

Monitoring Requirements When Taking Both Drugs

Patients on lisinopril and rosuvastatin should expect the same lab schedule they would need on either drug alone, with a few areas where overlapping organ-system effects deserve attention.

Renal function is the primary shared concern. Lisinopril reduces intraglomerular pressure by dilating the efferent arteriole, which can raise serum creatinine by 20-30% in the first weeks of therapy. This is expected and generally not a reason to stop the drug. Rosuvastatin, at the 40 mg dose, has been associated with proteinuria and hematuria in post-marketing surveillance, per the FDA label, though the JUPITER trial (N=17,802) showed no significant difference in renal adverse events between rosuvastatin 20 mg and placebo over a median 1.9 years of follow-up [7]. The 2013 ACC/AHA guideline on statin safety does not recommend routine urinalysis monitoring for rosuvastatin at standard doses [8].

Baseline and periodic monitoring for both drugs together should include:

• Serum creatinine and eGFR (before starting lisinopril, at 1-2 weeks, then every 6-12 months)
• Serum potassium (lisinopril can cause hyperkalemia, particularly in patients with CKD or diabetes)
• Fasting lipid panel (at baseline, 4-12 weeks after starting rosuvastatin, then annually)
• Hepatic transaminases (before starting rosuvastatin; repeat only if symptoms of hepatotoxicity develop, per 2013 ACC/AHA recommendations) [8]
• Blood pressure monitoring (standard for any antihypertensive)

Dr. Robert Eckel, past president of the American Heart Association and professor of medicine at the University of Colorado, has stated: "The combination of an ACE inhibitor with a statin represents one of the most evidence-supported dual-therapy approaches in cardiovascular prevention. These agents complement each other without pharmacologic conflict" [9].

Muscle-Related Side Effects: Separating Real Risk from Worry

Statin-associated muscle symptoms (SAMS) affect 5-10% of statin users in observational studies, though the SAMSON trial demonstrated that a large portion of these symptoms are attributable to the nocebo effect [6]. Among 60 patients, 90% of symptom burden reported during statin periods was also reported during placebo periods.

Rosuvastatin carries a lower risk of CYP-mediated muscle toxicity than simvastatin or atorvastatin precisely because it bypasses CYP3A4 entirely. The drugs most likely to cause statin myopathy do so by inhibiting the CYP3A4 enzyme and raising statin blood levels. Since lisinopril does not interact with CYP3A4 (or any CYP enzyme), it cannot increase rosuvastatin exposure through this mechanism or any other.

If a patient on both drugs reports muscle pain, the standard workup applies: check creatine kinase (CK), assess for alternative causes (exercise, hypothyroidism, vitamin D deficiency), and consider a statin holiday followed by rechallenge. The lisinopril does not change this algorithm.

ACE inhibitor-related muscle complaints are rare. Lisinopril's most common side effects are cough (reported in 5-10% of users), dizziness, headache, and hyperkalemia. None of these overlap mechanistically with statin myopathy.

Dose Adjustments in Special Populations

While no interaction-based dose adjustment is needed, both drugs require independent modifications in certain clinical scenarios. Renal impairment is the most relevant shared consideration.

For patients with eGFR <30 mL/min/1.73 m², rosuvastatin 5 mg is the recommended starting dose, with a maximum of 10 mg daily, according to the FDA label [4]. Lisinopril clearance is also reduced in renal impairment; the prescribing information recommends a starting dose of 2.5-5 mg daily for patients with creatinine clearance <30 mL/min [3].

In patients of East Asian descent, the 2018 AHA/ACC Cholesterol Guideline notes that rosuvastatin exposure may be approximately twofold higher due to OATP1B1 and BCRP polymorphisms more prevalent in this population, and recommends a starting dose of 5 mg [10]. This pharmacogenomic consideration is specific to rosuvastatin and is unrelated to lisinopril.

Elderly patients (age 75 and older) may need lower starting doses of both drugs. The STOPP/START criteria support continuing statins for secondary prevention in older adults but recommend caution with ACE inhibitor titration due to higher risk of hypotension and acute kidney injury [11].

The Cardiovascular Benefit of Dual Therapy

The rationale for combining antihypertensives with statins extends beyond treating two separate numbers. The ASCOT-LLA trial (N=10,305) randomized hypertensive patients already receiving antihypertensive therapy to atorvastatin 10 mg or placebo and found a 36% relative risk reduction in non-fatal myocardial infarction and fatal coronary heart disease with statin therapy added to blood pressure control [12].

While ASCOT-LLA used atorvastatin rather than rosuvastatin, the class effect of statins on LDL reduction is well established. Rosuvastatin 10 mg achieves approximately 46% LDL-C reduction, compared to 37% for atorvastatin 10 mg, based on comparative efficacy data from the STELLAR trial (N=2,431) [13]. Milligram for milligram, rosuvastatin is the most potent available statin.

The combined effect on 10-year ASCVD risk is substantial. A patient with systolic blood pressure reduced from 150 to 130 mmHg by lisinopril and LDL-C reduced from 160 to 85 mg/dL by rosuvastatin may see their calculated 10-year ASCVD risk drop by 40-60%, depending on other risk factors.

Dr. Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, noted in commentary on the JUPITER trial: "Statin therapy in the setting of controlled hypertension provides incremental benefit that cannot be achieved by blood pressure reduction alone. These are complementary interventions addressing distinct pathophysiologic processes" [7].

When to Contact Your Prescriber

Despite the absence of a pharmacokinetic interaction, patients should report specific symptoms promptly. Unexplained muscle pain, tenderness, or weakness (especially with fever or dark-colored urine) warrants CK measurement and possible statin discontinuation. A dry, persistent cough that develops after starting lisinopril should be reported, as switching to an angiotensin receptor blocker (ARB) resolves this ACE inhibitor class effect in nearly all cases.

Signs of angioedema (swelling of the face, lips, tongue, or throat) require emergency evaluation. This affects approximately 0.1-0.7% of lisinopril users and is more common in Black patients, per data published in the Annals of Allergy, Asthma & Immunology [14]. Rosuvastatin does not increase angioedema risk.

Patients should also report any signs of liver injury (jaundice, dark urine, severe fatigue, right upper quadrant pain) while on rosuvastatin, though clinically significant hepatotoxicity with statins is rare, occurring at a rate of approximately 1 per 100,000 patient-years according to a 2012 FDA Drug Safety Communication [15].

Routine follow-up with lab work at 6- to 12-month intervals keeps both drugs on track without requiring any special interaction-related testing.